Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Viatris (NasdaqGS:VTRS) with a Neutral ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As ...

Troyen A. Brennan, Harvard University. Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However ...

Introduction The global market for wearable injectors is swiftly growing, propelled by the rising need for self-administration of biologics and ...